## REMARKS

Claims 22 and 24, in the amended form presented herein, were allowed in the parent application, U.S. Ser. No. 08/128,020. Support for new claim 66, which depends from claim 22, is found in the specification, *e.g.*, at page 5, line 12.

Claims 21 and 23 are canceled as being redundant over pending claims.

Support for new claims which recite fragments comprising aspartoacylase epitopes (*e.g.*, claims 66 and 68) is found in the specification, *e.g.*, at page 5, line 12; and support for claims which recite a sequence identity of greater than 95% (*e.g.*, claim 67) is found, *e.g.*, at page 13, last four lines.

New claims 76-79 correspond to original claims 51-54, respectively. Claim 80 is an amended version of claim 20, the subject of the appeal in the parent, a copy of which is not being filed since the examiner has access to it in the parent. Claims 81-82 are supported, e.g., at page 16, lines 29-31.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

Anthony J. Zelano, Atty.Reg. No. 27,969
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410
Attorney Docket No.: SHUTT-1 C1

Date: February 4, 2002

## VERSION WITH MARKINGS TO SHOW CHANGES MADE

**IN THE SPECIFICATION:**

After the Title, please insert:

-- This application is a continuation of U.S. Ser. No. 08/128,020, filed Sept. 29, 1993, which is incorporated by reference herein in its entirety.--

**IN THE CLAIMS**:

*Please cancel claims 21 and 23 without prejudice or disclaimer.*

*Please amend the claims as follows:*

20. (Amended) A recombinant [An isolated] normal human aspartoacylase [polypeptide] capable of hydrolyzing N-acetyl aspartic acid to aspartate and acetate, having the amino acid sequence SEQ ID NO: 2, or a polymorphic form thereof.

22. (Amended) [A] An isolated mutant human aspartoacylase yhaign either an altered ability to hydrolyze N-acetyl-aspartic acid to aspartate and acetate, as compared with a normal human aspartoacylase, or incapable of hydrolyzing N-acetyl-aspartic acid to aspartate and acetate, and having the amino acid sequence SEQ ID NO: 2, except for said mutation, which is

E285 > A,

Y231 > X, and/or

A305 > E,

or an allelic variant of said mutant aspartoacylase.

24. (Amended) A mutant aspartoacylase of claim [23] 22, wherein the glutamic acid at amino acid position 285 is substituted by alanine.